Depression may occur at any time of the year, but the stress and anxiety of the holiday season—especially during the months of November and December (and, to a lesser extent, just before Valentine's Day)—may cause even those who are usually content to experience loneliness and a lack of fulfillment.
"[People] may start to question the quality of their own relationships," he says.
According to one 1999 Canadian study of patients treated by emergency psychiatric services during the Christmas season, the most common stressors were feelings of loneliness and "being without a family."
Facts & Statistics: The Truth About the Holiday Suicide Myth
The myth has been repeated so many times, most people consider it common knowledge: more people commit suicide between Thanksgiving and Christmas than at any other time of the year. Although it sounds reasonable, it simply isn't true.
Contrary to popular belief, December actually has the fewest suicide attempts of any month of the year. The facts, while seemingly encouraging, may be more complicated, however.
While it's true that suicide attempts tend to drop off just before and during the holidays, there is a significant uptick in suicide rates following Christmas—a 40 percent uptick, according to one large Danish study. Christmas itself seems to have a protective effect with regard to certain types of psychopathology, say researchers, but there is a significant rebound effect immediately following the holiday.
Although fewer people utilize emergency services or attempt suicide during December, there is an increase in certain other kinds of psychopathology, including mood disorders such as dysphoria and substance abuse.
by Pete Earley
“Why won’t you just take your medication? I take pills for my cholesterol every night and its no big deal?”
“Every psychiatrist we’ve seen has said you have a mental illness. Why won’t you accept it? Why would the doctors tell you that you’re sick, if it weren’t true?”
“Let’s look at when you were doing well and when you got into trouble. What was the difference? Medication. It was the difference. When you were on your meds, you were fine. And when you weren’t, you got into trouble. Can’t you see that?”
These quotes may sound familiar to you if you are a parent and have a a son or daughter with a severe mental illness. I’ve said everyone of them to my son, Mike.
It often is frustrating for us – parents — to understand why our children will not take anti-psychotic medication or take it only until they get better and then stop. The remedy seems so clear-cut to us, so simple - and watching them experience the mania, depression, and delusions that happen when they become psychotic is heartbreaking and horrific.
Early on, I tried every trick out there to get Mike to take his pills. Those of you who have read my book know that during one of his first breakdowns, I crushed his pills and mixed them into his breakfast cereal only to be caught by him. I snuck into his room and counted his pills too one day and when I discovered that he had stopped taking them, I followed the advice of a therapist who had told me that I needed to practice “tough love.” I told Mike that if he didn’t take his medication, he had to move out of my house. He did – that very same day.
Another time, I offered to pay him to take his medication — a $1 per pill.
It was my friend, Xavier Amador, author of the book, “I’m Not Sick, I Don’t Need Help” who finally convinced me to back off. “I can promise you, Pete,” he said, “your son knows exactly how you feel about medication. You don’t need to ever mention it to him again.”
And since that day, I haven’t. Not a word.
So why do persons with mental illnesses refuse to take their medication or stop taking them as soon as they become stable?
I am asked that question more than any other after I give a speech.
Let’s skip the obvious reasons –that some anti-psychotic medications can dull a person, make them feel physically lousy, kill their sex drive, cause them to gain weight or send them to bed exhausted even though they are already sleeping for 16 hours a day. Let’s ignore the fact that no one really knows the long term health impact that medication can cause on a person’s body.
Instead, let’s dig deeper.
One day, I asked Mike to explain to me in writing why he had struggled so much when it came to taking his medication.
The Ebola Drug Pipeline
The World Health Organization has said that it is ethical to use unproven drugs in the current epidemic. In the United States, the Food and Drug Administration has granted expanded access to several experimental drugs for use on Ebola patients. The drugs prevent replication of Ebola virus and the vaccines work by triggering an immune response. The drugs and vaccines listed here are in clinical trials and have received support for further development, according to the Centers for Disease Control and Prevention.
Andeonia Patients Restors the Ability to Experience PleasureWithin Minutes in Depressed Patients Within Minutes with Ketamine
There are many faces to depression: sadness, hopelessness, trouble sleeping, lack of motivation, an inability to experience pleasure.
That last one has a medical name—anhedonia—and people experiencing it often no longer enjoy activities that used to bring happiness. Anhedonia is not found just in depression; it can be an important part of other disorders, including schizophrenia, obsessive-compulsive disorder and addiction.
In a study published this month in Translational Psychiatry, researchers have found that a drug called ketamine can help quickly reverse anhedonia in patients with treatment-resistant bipolar depression (also known as manic-depression or bipolar disorder).
Ketamine has previously been shown to help rapidly reverse other aspects of depression in a number of studies; doctors use the drug to treat patients at several hospitals around the country, although it remains illegal to possess without a prescription and hasn’t yet been approved by the Food and Drug Administration for psychiatric purposes. On the party drug circuit it’s sometimes called “Special K” and is abused for its anaesthetic and hallucinogenic effects.
The researchers found that a single injection of ketamine led to a significant improvement in normal pleasure-seeking behavior in as little as 40 minutes, and this dramatic improvement lasted as long as two weeks for some of the 36 participants.
You've seen the TV commercials, the person in black and white and sad while they watch their friends and family in color happy as can be? Then the sad individual gets help, sees the world in color and has a dog run into frame to play with them, or they are suddenly on the couch petting their beloved cat. Well, there's a reason for that, pets can help individuals with depression/illnesses/anxiety.
"Pets offer an unconditional love that can be very helpful to people with depression," says Ian Cook, MD, a psychiatrist and director of the Depression Research and Clinic Program at UCLA.
Depression affects millions of individuals in the USA alone. A lot of people reading this suffer from some form or know someone who does. A pet might not be right for everyone, so don't just show up with a pet one day for someone you know with depression.
Study finds it might be safer alternative to standard antipsychotics
TUESDAY, Feb. 18, 2014 (HealthDay News) -- The antidepressant Celexa shows promise in easing the agitation people with Alzheimer's disease often suffer, and may offer a safer alternative to antipsychotic drugs, a new study finds.
"Agitation is one of the worst symptoms for patients and their families: it puts the Alzheimer's patient at risk for other system overloads (cardiac, infection), wears them out physically, and exhausts caregivers and families," noted one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox Hill Hospital in New York City.
He said that while antipsychotic drugs are typically used to help ease the agitation, they are also associated with a higher risk of death for Alzheimer's patients, so safer alternatives would be welcome.
The new study was led by Dr. Constantine Lyketsos, director of the Johns Hopkins Memory and Alzheimer's Treatment Center in Baltimore. It included 186 Alzheimer's patients with agitation symptoms such as emotional distress, aggression, irritability, and excessive movem
The diagnosis of bipolar disorder in her 20s came as a relief to Hope Richardson. There was finally a name for what she felt and something that could be done, she said. Because mental illness is a lifelong condition, staying well takes effort, and she's mindful of that every day.
Once afraid of others not liking her and unable to stand up for herself, Richardson said she often walked around with her head down and hair covering her face. She went through bouts of depression and struggled with anger, manic episodes and suicidal thoughts.
Early on, she was hesitant to talk about her condition.
"I didn't want people to know. I was kind of embarrassed and ashamed," said Richardson, 44, of Des Moines.
Through therapy and support, she has learned to "live with," rather than "suffer," mental illness and says the only way to end stigma is to educate others.
She's part of a group of trained speakers who open up about their disorders through In Our Own Voice, a public awareness program sponsored by the National Alliance for Mental Illness Greater Des Moines. The local chapter began offering the program last fall.
Sharing their stories serves as a type of ongoing therapy for the speakers and a chance to paint a realistic picture of mental illness, which affects one in four adults — about 61.5 million Americans every year. One in 17, or 13.6 million Americans, live with a serious mental condition such as schizophrenia, major depression or bipolar disorder.
Three In Five Patients Feel Depressed Or Anxious As A Result Of Their Pain22 Oct 2008
Despite treatment efforts, chronic pain management is failing one in three (n = 377) patients suffering from severe chronic pain, and three in five (n = 336) patients feel moderately or extremely anxious or depressed as a result of their pain. Whilst eight in ten (n = 377) chronic pain patients are taking prescription medication, one in two (n = 307) of these patients are suffering the additional burden of side effects. These are the findings released today from the interim data from PainSTORY (Pain Study Tracking Ongoing Responses for Year), the first survey of its kind to provide in-depth insight into how chronic pain impacts the lives of patients over one year in 13 European countries.
Today's data provide a picture of patients' lives over the three months since the survey was initiated and shows that despite consultation with a healthcare professional and treatment patients are still struggling with their pain, impacting patients' quality of life.
"Interim results from PainSTORY are important and highlight that patients continue to suffer from chronic pain despite seeking medical attention," said Dr Varrassi, President of the European Federation of IASP Chapters, a leading pain society. "The medical community need to provide adequate treatment for patients in moderate-severe pain, but there seems to still be barriers that need to be overcome".
Since their initial interview three months ago, for 77 percent (n = 377) of patients the level of pain they experience has either stayed the same or even deteriorated further. 33% (n=377) of patients continue to suffer from severe chronic pain, 15% (n = 377) had progressed from moderate to severe pain, and 1% (n = 377) from mild to severe pain.
PainSTORY shows that both the physical and psychological aspects of patients' lives are affected by their pain. Six out of ten (n = 336) patients are experiencing problems walking about and over half (n= 336) experience problems sleeping. The influence of pain also extends into patients' working lives, and almost half (n = 195) have changed the way they work. "I couldn't interact. The pain trapped me and I couldn't socialise. I felt like a prisoner of the pain and really conditioned by it," said patient 14 from the United Kingdom.
Today's data show patients are being prescribed suboptimal treatment for their pain. Of the 81 percent (n = 377) of patients in moderate-severe pain on prescription medication, only 13 percent were prescribed strong opioids. Over half of patients were suffering at least one side effect as a result of their prescribed medication (n = 162), including constipation, dizziness and drowsiness, which are common symptoms for both weak and strong opioids.
"Side effects are affecting these patients. Patients are finding themselves in situations where they need to choose between using pain relief medications, or compromising their pain management by not taking medications to avoid the burden of side effects," stated Professor Erdine from the World Institute of Pain. "We are interested to see the next wave of results for PainSTORY. There has already been some interesting issues that have been brought to light. This survey demonstrates the pressing need for improved management of pain across Europe."
About the survey
PainSTORY (Pain Study Tracking Ongoing Responses for a Year) is the first study of its kind to track patients with chronic pain for a year, providing a picture of the lives of people living in pain, and the management of pain in 13 European countries.
Baseline results from the study show that chronic pain has a significant impact on the daily lives of patients. The survey aims to better understand the management of chronic pain across Europe.
The PainSTORY survey is being conducted by an independent research company, IPSOS, in collaboration with the following independent third parties:
- European Federation of IASP Chapters
- World Institute of Pain
- Arthritis and Rheumatism International
- OPEN Minds
The survey is sponsored by a restricted educational grant from Mundipharma International Limited.
PainSTORY recruited patients suffering from non-malignant (osteoarthritis, back pain / lower back pain, osteoporosis, neuropathic pain, mixed pain, other long term pain), moderate to severe (rate 5-10 on a pain scale) chronic pain (i.e. lasting for more than three months). Respondents are studied for 12 months. The research is being carried out in 13 countries across Europe: United Kingdom, France, Germany, Switzerland, Italy, Spain, Ireland, Belgium, Sweden, Denmark, Finland, Netherlands, Norway by an independent research company, IPSOS.
The study consists of four waves of qualitative interviews between April 2008 and March 2009. Interim engagement activities between the four waves are sent to patients to provide additional insight, such as diaries and lifebooks. Comparisons between baseline data and subsequent wave results will show how the impact of pain and pain management changes over the course of a year.
About the European Week Against Pain
The European Week Against Pain (EWAP) which takes place annually, was started as part of the European Federation of IASP Chapters' (EFIC's), Europe Against Pain Initiative, in October 2001. EWAP aims to create more awareness of pain as a major healthcare problem amongst the general public, healthcare workers and healthcare policy makers.
The theme of this year's EWAP is fibromyalgia, a widespread musculoskeletal pain and fatigue disorder that occurs predominately in women. Unexplained widespread pain occurs in about 10% of the general adult population in Western countries, with approximately half of those affected meeting American College of Rheumatology (ACR) classification criteria for fibromyalgia.
The PainSTORY survey was sponsored by a restricted educational grant from Mundipharma International Ltd, Cambridge, England
Forum Admins note: results from the pain story is in the link below. 3-2010